Abstracts

541 – Autologous IgGs Mediate Log Reductions in HIV Infection in a PTC, Contributing to ART-Free Remission

Background In people living with HIV on suppressive ART, the latent reservoir is composed of archived viral variants that are either sensitive or resistant to autologous neutralizing antibodies (aNAbs), with the latter capable of causing rebound following treatment interruption. We hypothesized ART-free virologic control might be achieved if aNAbs developed to neutralize all inducible, replication-competent…

565 – Multiomics Clustering Reveals Distinct HIV Reservoir Profiles in the 2000HIV Cohort

Background Multi-omics data integration offers potential to uncover hidden patterns among people living with HIV (PLWH). This study aimed to identify clusters of individuals with distinct viral reservoir characteristics and multi-omics profiles in the 2000HIV cohort. Methods Multi-omics data from 1,236 PLWH in the 2000HIV cohort (NCT03994835) were analyzed, including gene expression (58,347 genes, bulk…

405 – Robust CD8+ T-Cell Proliferation and Stem-Like Memory Phenotype Linked to HIV Post-Treatment Control

Background Post-treatment controllers (PTCs) of HIV control viremia to low or undetectable levels following discontinuation of ART. Previous studies have suggested a lack of association between ex vivo HIV-specific CD8+ T cell responses and post-treatment control. Here we extended beyond ex vivo evaluations to assess the proliferative capacity of HIV-specific CD8+ T cell responses in…

426 – Unadjuvanted CD40.HIVRI.ENV Vaccine Late Boost Induces Durable Immune Responses: ANRS/VRI06 Trial

Background CD40.HIVRI.Env is a gp140 Env (Clade C 96ZM65) fused to an anti-CD40 mAb to target CD40-expressing dendritic cells. The ANRS/VRI06 phase I trial (NCT04842682) enrolled 72 non HIV-infected volunteers to receive either 0·3, 1·0, or 3·0 mg of CD40.HIVRI.Env (TLR3-Hiltonol® adjuvanted) alone or co-administered with DNA-HIV-PT123 at weeks (W) 0, 4 and 24, randomized…

483 – Persistence of Seroprotection After Modified Hepatitis B Vaccine Schedule in People Living With HIV

Background To evaluate the persistence of seroprotection, anti-HBs titers, and anamnestic response to challenge dose, following the Brazilian Ministry of Health’s (MS) recommended HBV vaccination schedule in people living with HIV/AIDS (PLHIV). Methods Intervention study in PLHIV followed up in the outpatient clinics of the Infectious disease department at Federal University Hospital in Rio de…

1042 – HIV-Specific T-Cell Dynamics in Acute-Treated, Chronic-Treated, and Elite Controller People With HIV

Background Early initiation of ART can preserve immune function and is associated with increased incidence of post-treatment control of HIV, yet differences in HIV-specific immune responses between people with HIV (PWH) who initiated ART during acute vs. chronic infection are poorly defined. The extent to which immune responses in early- and late-treated PWH differ from…

414 – Structural Insight into the High- and Low-Affinity Alleles of Human and Macaque FcγRIIA (CD32A)

Background Rhesus macaques (RM), Macaca mulatta, are one of the main nonhuman primate models for the testing of vaccines and antibody-based therapeutics. Macaques, like humans, have high and a low affinity alleles of FcγRIIA (CD32A) which is expressed on macrophages, dendritic cells and other antigen presenting cells. The polymorphism in FcγRIIA potentially influences the ‘vaccinal…

561 – In-Depth Evaluation of the Intact Proviral DNA Assay for the Quantification of HIV-1 Reservoir

Background Accurate quantification of the HIV-1 reservoir is critical in understanding HIV-1 persistence and evaluating cure strategies. The Intact Proviral DNA Assay (IPDA), a droplet digital PCR assay that simultaneously targets the HIV-1 packaging signal (psi) and env, is widely used to quantify the intact or rebound-competent reservoir but has not been thoroughly evaluated. We…

479 – T-Cell Immunity of PHH-1V COVID-19 Vaccine in PWH and Adults With Immunosuppressive Conditions

Background Protective vaccines became an urgent need during the COVID-19 pandemic. People with immunodeficiencies particularly benefit from COVID-19 vaccination. PHH-1V (BIMERVAX®) is an authorized and adjuvanted recombinant vaccine based on a dimeric RBD of Alpha/Beta SARS-CoV-2 variants. HH-4 was a Phase IIb/III, open-label, single-arm, multi-center study (NCT05303402) to evaluate the humoral and cellular immune response…

456 – IFI16 Controls PVR and Gal-9 Expression and Its Targeting Improves Immunotherapy Against HIV-1

Background Stimulation of HIV-1 specific CD8+ T cells with Monocyte-derived dendritic-cells (MDDC) in an attractive immunotherapy strategy against HIV-1. However, chronic inflammation in People with HIV (PWH) has been linked to low CD4/CD8 T cell ratios, activation of the inflammasome and may affect the expression of checkpoint ligands in Mo, limiting efficacy of MDDCs. Here,…